速递｜聚焦减肥医疗器械，13亿估值糖吉医疗启动港股IPO！

Core Viewpoint - The article discusses the IPO application of Tangji Medical Technology Co., Ltd., which focuses on the development and commercialization of medical devices related to metabolic diseases, particularly obesity and type 2 diabetes [4][5]. Market and Industry Overview - Tangji Medical operates in the healthcare sector related to metabolic diseases, which includes obesity, overweight, type 2 diabetes, and metabolic-associated fatty liver disease (MASH). These chronic diseases pose a significant burden on global healthcare systems, with approximately 6.7 million deaths related to diabetes globally in 2021, including about 1.4 million in China. The corresponding medical expenditures were $966 billion globally and $165 billion in China [5]. - The demand for medical solutions addressing metabolic diseases is expected to grow due to aging populations, lifestyle changes, and increased disease screening rates, providing substantial market opportunities for medical devices [5]. Company Development and Product Introduction - Established in 2016, Tangji Medical has focused on the research and industrialization of medical devices, expanding its presence in both domestic and international markets. The company operates through multiple subsidiaries, including Jikang Medical in Quzhou and Tangji Health Technology in Tianjin, and has established overseas entities in Hong Kong and Singapore [8]. - The product portfolio includes a gastric bypass stent system that reduces sugar and fat absorption and stimulates GLP-1 secretion to lower blood sugar and aid weight loss. This product has received approval from the Chinese National Medical Products Administration and is recognized as a "breakthrough device" by the FDA in the U.S. Additionally, the company has launched a digital health management software for obesity, which is the first of its kind to receive medical device registration in China [8]. Financial Status and Stage Assessment - Tangji Medical is currently not profitable, primarily due to high R&D expenditures and ongoing investments in industrialization and market expansion. The company has accumulated a certain scale of tax losses in China. Similar to other early-stage medical device companies, Tangji Medical is still in the process of accumulating R&D results and market presence [9]. - The company aims to build a product system focused on chronic and metabolic disease needs, indicating a long-term strategy rather than a short-term performance-driven IPO case. The market potential remains strong due to the rising burden of metabolic diseases, but the company's success will depend on the registration progress, commercialization capabilities, and clinical application of its core products [9]. Market Outlook - The market for Tangji Medical is expected to grow significantly due to the increasing prevalence of obesity and metabolic diseases. The company's advancements in R&D and clinical applications, particularly the approval of the gastric bypass stent system and the expansion into digital health management, are likely to enhance its market share [10]. - The IPO of Tangji Medical is attracting considerable attention in the medical device sector, especially in the weight loss and metabolic disease fields. As products gradually enter the market, the company is positioned to become a leading player in this domain [10].